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Introduction:Over the last decade MM diagnosis and therapy have greatly im-
proved; notably due to an increasing number of “novel agents” (NA). Anti-MM-
therapy has gained complexity, therefore their continuous evaluation is relevant.
Analyses of chemotherapy (CTx) management, including efficacy and costs, have
grown due to the numerous anti-MM treatment choices. In order to determine
MM therapy sequence -therein allowing efficacy and costs- we performed data
assessment of clinical practice patterns. Substance use was analyzed in view of
treatment lines, changes in 2 treatment periods (2005-2012 vs. 2013-2017), “MM-
pathway conformity” and costs. Methods: Data on therapy composition were col-
lected for the years 2005 to 2017, separating 2 treatment periods for 1st, 2nd and
3rd-line therapy (Figure 1); the time cut-off being chosen to discriminate between
NA- and non-NA-based regimens, and first generation PI- (bortezomib [BOR]),
IMiD- (thalidomide [THAL], lenalidomide [LEN]) and second generation NA-
use. Results:Pt characteristics were representative for tertiary centers; the median
age was 63 years (27-89), 54% were 60-79 and 14% >80 years old. The ISS was
predominantly advanced (II/III:62%). Pts showed substantial comorbidities and
were classified as fit vs. intermediate-fit or frail according to the R-MCI in 33%
and 67%, respectively. Of interest, 33% of pts could be enrolled in clinical trials
(CTs) and 88% received 1st-line treatment at our center. Expectedly, numbers of
pts decreased with subsequent lines of treatment, albeit the median time to 2nd-
line therapy due to progression amounted to 2 years: 100% (275 pts) received 1st-
line, 54% 2nd-line and 35% 3rd-line treatment (Figure 1). As depicted in Figure
1, 1st-line conventional CTx (cCTx) alone was rare and substantially declined
over time from 12% 2005-2012 to 1% in 2013-2017. 73% were treated with BOR
in 1st-line, 63 of 106 reinduced pts received BOR in 2nd- or 3rd-line. IMiD 2nd-
and 3rd-line treatment was also common within different regimens and the com-
bination of 2 NA increased over time. The use of second generation NA in 2nd-
and 3rd-line treatment notably amplified in 2013 to 2017 in line with their ap-
proval. Our analysis also determined that 44% of second generation NA protocols
were administered outside CTs, mainly due to tight CT inclusion criteria. Main-
tenance was performed in 57% of pts, predominantly with LEN and within
DSMM CT protocols. Conclusion:NA combinations were used predominantly:
while expectedly, BOR plays an important role in induction, LEN was subse-
quently used for maintenance and in outpt-regimens. A significant percentage of
second generation NA was given outside CTs, displaying the fast implementation
of MM-guideline care into clinical practice. Costs and efficacy results will be
shown at the meeting, including via detailed review of the literature.
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Figure 1. Clinical practice 2005-2012 vs. 2013-2017.
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Therapeutic options have greatly expanded & designing clinical trials that
will impact on the delivery of a new standard of care has arrived at an inter-
esting cross road. MM is a heterogeneous disease as are the patients it affects.
It is time to consider a new clinical trial research strategy that answers these
questions, as this is the fundamental principles of Better Research, Better im-
pact. Designing clinical studies that utilise biomarkers is the key to stratified
research studies in the future. These biomarkers include determinants of host
response biology (HRB), tumour molecular landscaping & response
biomarkers (minimal residual disease; MRD). HRB determinants can include
end-organ damage parameters, clinical scoring systems of fitness, immune
system quantitation and serial markers of age-related inflammation. Less fit
patients represent a substantial proportion of newly diagnosed patients re-
quiring treatment. Whilst age does not necessarily equate to fitness to tolerate
therapy nonetheless age-related inflammation is perhaps the most important
physiologic correlate of the age-related frailty syndrome. Recent clinical
scoring systems which are able to delineate patients into fit, unfit & frail
groupings, with respective differences in PFS and OS in clinical trials have
been highlighted. The clinical relevance of genomic heterogeneity in MM
(copy number variances, translocations & mutational aberrations) is reflected
in the fact that a significant proportion of MM patients relapse early & show
short survival with current therapies. Defining these high & ultra-high risk
patients at diagnosis to stratify treatment & offer the prospect of improving
outcomes remains a laudable goal. Two validated molecular approaches for
risk prediction widely used include genetic risk profiling [e.g. del(17p),
t(4;14)] & gene expression risk profiling, [e.g. EMC92]. However, what is
the most relevant clinical intervention for such higher risk patients remains
to be defined. In addition, in patients without such risk factors, could they
be more appropriately treated using stop/start designations such as time lim-
ited maintenance? The presence of MRD is a reproducible and independent
predictor of both progression-free (PFS) and overall (OS) survival outcomes
in MM. MRD is considered as a potential surrogate / intermediate end point
for regulatory purposes. However, should MRD negativity not be utilized to
direct treatment? Can MRD be used as a “stop/go” marker e.g. can mainte-
nance strategies be safely withdrawn? If patients persist as MRD positive
should we look to escalating on-gong therapy? Lastly, when real world
databases are interrogated, it is clear that clinical studies, especially regula-
tory phase III studies, do not represent the patients we treat day-by-day in
our clinic, equating to 40-50% of the true myeloma population. This repre-
sents a significant issue when translating the efficacy and tolerability of treat-
ment regimens into practice as we see it. Therefore, in designing studies
going forward, we need to be mindful of a number of disease and patient re-
lated determinants, realising the mantra that “one size doesn’t fit all” which
will inevitably allow us to deliver Better Research, Better Impact.
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In the recent years, six new agents have been approved by FDA and EMA
(Pomalidomide, Carfilzomib, Panobinostat, Elotuzumab, Ixazomib and Dara-
tumumab). In relapsed Multiple Myeloma (MM), randomized studies compar-
ing standard doublets(bortezomib-dexamethasone or lenalidomide-
dexamethasone ) versus triplets with the addition of one of these six agents,
have all shown a significant improvement of PFS and sometimes of OS.  There-
fore these triplets are becoming new standards for the treatment of relapsed
MM. However, all these agents are very expensive, and the cost of one month
of treatment with triplets may reach 150 000 USD. In many countries, these
costs are not affordable when they are not covered by public or private insur-
ances. This situation raises the question of equal access to treatment for all pa-
tients. Even in rich countries, government policies for reducing health-care
costs may induce limited prescriptions or reimbursement/ pricing delays . This
question of affordability/availability is a challenge for cancer treatment in gen-
eral. In MM it is  becoming critical because the number of patients treated and
the duration of treatments are increasing dramatically thanks to the recent ther-
apeutic advances. There are many stakeholders who may play a role in trying
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